Healthy Outcome under Olanzapine Treatment in a Pregnant Woman

J. Stingl; A. Berghöfer; D. Bolk-Weischedel

doi:10.1055/s-2000-7974

Pharmacopsychiatry, Inhaltsverzeichnis

Pharmacopsychiatry 2000; 33(2): 78-80
DOI: 10.1055/s-2000-7974

Case Report

Georg Thieme Verlag Stuttgart ·New York

Healthy Outcome under Olanzapine Treatment in a Pregnant Woman

J. Stingl¹ , A. Berghöfer² , D. Bolk-Weischedel²

¹Institute for Clinical Pharmacology, Charité, Humboldt University Berlin, Germany
²Department of Psychiatry Freie Universität Berlin, Germany

Abstract

Our report focuses on the case of a pregnant women with recurrent, paranoid schizophrenia. The patient was treated with Olanzapine from the 18^th gestational week until delivery and during breast-feeding. No adverse events occurred during pregnancy, and the outcome was healthy. After delivery, the plasma level of olanzapine in the infant was one-third of the maternal plasma level, and during breast-feeding, it decreased to an undetectable limit.

Volltext

Referenzen

References

1 Altshuler L L, Cohen L, Szuba M P, Burt V K, Gitlin M, Mintz J. Pharmacologic management of psychiatric illness during pregnancy: dilemmas and guidelines. Am. J. Psychiatr.. 1996; 153 -606
2 Ananth J. Side effects in the neonate from psychotropic agents excreted through breast-feeding. Am. J. Psychiatr.. 1978; 135 -805
3 Brazelton T B. Effect of perinatal drugs on the behaviour of the neonate. Am. J. Psychiatr.. 1970; 126 1261-1266
4 Cohen L S, Rosenbaum J F. Psychotropic drug use during pregnancy: weighing the risks. J. Clin. Psychiatry.. 1998; 59 (suppl. 2) 18-28
5 Crawford A MK, Beasley C M Jr, Tollefson G D. The acute and long-term effect of olanzapine compared with placebo and haloperidol on serum prolactin concentrations. Schiz. Res.. 1997; 26 41-54
6 Dickson R A, Dawson D T. Olanzapine and pregnancy. Can. J. Psychiat.. 1998; 43 196-197
7 Dieulangard P, Coignet J, Vical J C. Sur un cas d'ectro-phocome¿lie, peut-tre d'origine medicamenteuse (On a case of congenital dwarfism, perhaps of the origin of medication) Bull. Lippincott-Raven publishers.. 1966; 18 85-87
8 Edlund M J, Craig T J. Antipsychotic drug use and birth defects: an epidemiologic reassessment. Compr. Psychiat.. 1984; 25 32-37
9 Hagopian G S, Meyers D B, Markham J K. Teratology studies of LY170053 in rats and rabits. Teratology.. 1987; 35 60
10 Hanson G, Oakley G, Ruddock V M, Townsend J, Meade T W. Haloperidol and limb deformity (letter). JAMA. 1975; 231 26
11 Koren G, Pastuszak A, Shinya I. Drugs in pregnancy. N. Engl. J. Med.. 1998; 338 1128-1137
12 Liebermann J, Safferman A Z. Clinical profile of clozapine: adverse reactions and agranulozytosis. In: Clozapine in treatment resistant schizophrenia: a scientific update. Lapierre Y., J.B. London (eds.) Royal Society of Medicine 1992
13 McCollan F W, Heggeness L. Limb malformations following maternal use of haloperidol. JAMA. 1975; 231 62-64
14 Meltzer F Y, Goode D J, Schyve P M, Young M, Fang V S. Effect of clozapine on human serum prolactin levels. Am. J. Psychiat.. 1979; 136 1550-1555
15 Milkovich L, Van den Berg B J. An evaluation of the teratogenicity of certain antinauseant drugs. Am. J. Obstet. Gynecol.. 1976; 125 -248
16 Orr S, Miller C. Maternal depressive symptoms and the risk of poor pregnancy outcome: review of the literature and preliminary findings. Epidemiol. Rev.. 1995; 17(1) 165-171
17 Patel A J, Barochovsky O, Lewis P D. Psychotropic drugs and brain development: effects on cell replication in vivo and in vitro. Neuropharmacol.. 1981; 20 1243-1249
18 Perkin M R, Bland J M, Peacock J L. The effect of anxiety and depression during pregnancy on obstetric complications. Br. J. Obstet. Gynaecol.. 1993; 100 629-634
19 Rieder R O, Rosenthal D, Wender P, Blumenthal H. The offspring of schizophrenics. Fetal and neonatal deaths. Arch. Gen. Psychiat.. 1975; 32 200-211
20 Rumeau-Rouquette C, Goujard J, Huel C. Possible teratogenic effects of phenothiazines in human beings. Teratology.. 1977; 15 57-64
21 Slone D, Suskind V, Heinonen O P, Monson R R, Kaufman D W, Shapiro S. Antenatal exposure to the phenothiazines in relation to congenital malformations, perinatal mortality, birth weight and intelligence quotient score. Am. J. Obstet. Gynecol.. 1977; 128 -488
22 Steer R A, Scholl T O, Hediger M L, Fischer R L. Self-reported depression and negative pregnancy outcomes. J. Clin. Epidemiol.. 1992; 45 1093-1099
23 Stoner S C, Sommi R W jr, Marken P A, Anya I, Vaughn. Clozapine use in two full-term pregnancies. J. Clin. Psychiatr.. 1997; 58 364-365
24 Tenyi T, Trixler M, Vereczkey G, Dorka A. (Use of clozapine during pregnancy) Clozapine alkalmazasarol terhesseg soran. Orv. Hetil.. 1994; 135 1967-1969
25 Thiels C. Pharmacotherapy of psychiatric disorder in pregnancy and during breastfeeding: a review. Pharmacopsychiat.. 1987; 20 133-146
26 Van Waes A, Van de Velde E. Safety evaluation of haloperidol in the treatment of hyperemesis gravidarum. J. Clin. Pharmacol.. 1969; 9 -226
27 Waldman M, Saffermann A. Pregnancy and clozapine. Am. J. Psychiatry.. 1993; 150 168-169
28 Zuckerman B, Bauchner H, Parker S, Cabral H. Maternal depressive symptoms during pregnancy and newborn irritability. J. Dev. Behav. Pediatr.. 1990; 11 (8) 190-194

MD Julia Kirchheiner,

Institut für Klinische Pharmakologie Universitätsklinikum Charité Humboldt-Universität zu Berlin

Schumannstraße 20-21

D-10098 Berlin

Germany